Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan

Semin Hematol. 2010 Apr;47 Suppl 1:S5-7. doi: 10.1053/j.seminhematol.2010.01.015.

Abstract

The most common subtype of T-/natural killer (NK) cell lymphoma in Japan is adult T-cell leukemia-lymphoma (ATL), which is associated with the human T-cell lymphotropic virus type I (HTLV-1). The investigators in Japan have conducted several clinical trials on multi-agent chemotherapy and stem cell transplantation for patients with ATL. They have also initiated several new clinical trials with a number of agents: an anti-CCR4 antibody, KW-0761; forodesine, a purine nucleoside phosphorylase inhibitor; and lenalidomide, an immunomodulatory agent. Clinical trials with pralatrexate, a folate analog, and denileukin diftitox, an immunoconjugate, are under discussion for patients with ATL and peripheral T-cell lymphoma (PTCL).

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Clinical Trials as Topic*
  • Combined Modality Therapy
  • Drugs, Investigational / therapeutic use
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunologic Factors / therapeutic use
  • Japan
  • Lenalidomide
  • Leukemia-Lymphoma, Adult T-Cell / drug therapy*
  • Leukemia-Lymphoma, Adult T-Cell / epidemiology
  • Leukemia-Lymphoma, Adult T-Cell / surgery
  • Multicenter Studies as Topic
  • Purine Nucleosides / therapeutic use
  • Pyrimidinones / therapeutic use
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Drugs, Investigational
  • Immunologic Factors
  • Purine Nucleosides
  • Pyrimidinones
  • forodesine
  • Thalidomide
  • Lenalidomide
  • mogamulizumab